In response to the variable rate of ALK expression assessed via IHC on the cell surface, recent authorship has recommended the use of next-generation sequencing (NGS) to further interrogate IMT cases that test negative for ALK1 on IHC [14]. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.